Plecanatide acetate, an analogue of Uroguanylin, is an orally activeguanylate cyclase-C (GC-C) receptoragonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with anEC₅₀of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis^[1][2][3].

EC50: 190 nM (guanylate cyclase-C receptor, T84 cells)^[1]

Plecanatide (1 nM-10 μM) activates GC-C receptor to stimulate cGMP synthesis in a dose-dependent manner with EC₅₀of 190 nM in T84 cells^[1].

Plecanatide (0.5 and 2.5 mg/kg, p.o.) ameliorates spontaneous and chemically induced colitis after treatment for 7 days in BALB/c mice, and 14 days in TCRα^-/-mice^[1].
Plecanatide (0.005-5 mg/kg, once daily for 7 days) also shows anti-inflammatory activity in dextran sulfate sodium (DSS) and trinitrobenzene sulfonic (TNBS)-induced colitis in BDF-1 mice^[1].

1741.94

Solid

C₆₇H₁₀₈N₁₈O₂₈S₄

1075732-84-1

Asn-Asp-Glu-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu (Disulfide bridge: Cys4-Cys12; Cys7-Cys15)

NDECELCVNVACTGCL (Disulfide bridge: Cys4-Cys12; Cys7-Cys15)

普卡那肽醋酸盐；醋酸普卡那肽

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)